State of Tennessee Treasury Department bought a new position in Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to its most recent filing with the SEC. The firm bought 100,000 shares of the biotechnology company’s stock, valued at approximately $5,707,000. State of Tennessee Treasury Department owned approximately 0.09% of Bioverativ as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Woodford Investment Management Ltd acquired a new stake in Bioverativ in the 3rd quarter worth approximately $85,455,000. State of Wisconsin Investment Board acquired a new stake in Bioverativ in the 3rd quarter worth approximately $1,259,000. Stevens Capital Management LP acquired a new stake in Bioverativ in the 3rd quarter worth approximately $4,319,000. Chicago Equity Partners LLC acquired a new stake in Bioverativ in the 3rd quarter worth approximately $532,000. Finally, Old Mutual Global Investors UK Ltd. acquired a new stake in Bioverativ in the 3rd quarter worth approximately $96,827,000. Institutional investors own 95.16% of the company’s stock.
TRADEMARK VIOLATION WARNING: “State of Tennessee Treasury Department Takes Position in Bioverativ Inc (BIVV)” was originally posted by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.thestockobserver.com/2017/11/14/state-of-tennessee-treasury-department-takes-position-in-bioverativ-inc-bivv.html.
Bioverativ Inc (BIVV) opened at $53.91 on Tuesday. Bioverativ Inc has a 1-year low of $40.00 and a 1-year high of $64.41.
Bioverativ (NASDAQ:BIVV) last posted its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.25. The firm had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. Bioverativ’s revenue for the quarter was up 27.2% on a year-over-year basis. equities analysts expect that Bioverativ Inc will post 2.45 earnings per share for the current year.
Several analysts have commented on BIVV shares. Jefferies Group LLC restated a “buy” rating and set a $70.00 price objective (up from $67.00) on shares of Bioverativ in a research note on Wednesday, August 9th. Cowen and Company restated a “buy” rating and set a $80.00 price objective on shares of Bioverativ in a research note on Friday, August 4th. Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research note on Wednesday, September 20th. Zacks Investment Research cut shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Finally, Evercore ISI started coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Bioverativ presently has a consensus rating of “Hold” and a consensus price target of $61.73.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.